[1] WANG JingGUO JinyuanYANG HailongLI GangZHANG Yunfeng,.Effect of Modified Wushen Decoction on Hemorheology and Cardiac Function in Patients with Myocardial Infarction after PCI [J]. Modern Traditional Chinese Medicine, 2024, (01): 56-61. [doi: 10.13424/j.cnki.mtcm.2024.01.013]
Effect of Modified Wushen Decoction on Hemorheology and Cardiac Function in Patients with Myocardial Infarction after PCI
- Article number:
- 1672-0571(2024)01-0056-06
- Keywords:
- Key words:Acute myocardial infarction; Percutaneous coronary intervention; Heart function; Hemorheology; Inflammatory factors
- ZTFLH:
- R256.22
- Code:
- A
- Abstract:
- Abstract：Objective To observe the effects of modified Wushen decoction on cardiac function and hemorheology in patients with acute myocardial infarction after percutaneous coronary intervention (PCI).Methods 88 patients with acute myocardial infarction treated with PCI in our hospital from April 2020 to May 2022 were selected and randomly divided into a control group (44 cases，treated with conventional Western medicine after surgery) and a Wushen decoction group (44 cases，treated with conventional Western medicine and modified Wushen decoction after surgery).Blood rheology，heart function，serum inflammatory factors，oxidative stress indicators were measured and compared between the two groups before and after treatment，and cardiovascular adverse events and adverse reactions were recorded.Results After treatment，the three hemorheological indicators in the Wushen decoction group were significantly lower than those in the control group (P＜0.05)；After treatment，the levels of C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) in the Wushen decoction group were significantly lower than those in the control group (P＜0.05)；After treatment，the serum MDA level in the Wushen decoction group was lower than that in the control group，while the SOD level was higher than that in the control group (P＜0.05)；After treatment，the left ventricular ejection fraction (LVEF) in the Wushen decoction group was significantly higher than that in the control group，and the left ventricular end systolic diameter (LVESD) was significantly lower than that in the control group (P＜0.05)；The incidence of cardiovascular adverse events in the Wushen decoction group was significantly lower than that in the control group (P＜0.05)；There was no significant difference in the incidence of adverse reactions between the Wushen decoction group and the control group (P＞0.05).Conclusion Modified Wushen decoction can significantly improve hemorheology and cardiac function in patients with acute myocardial infarction after PCI，reduce the incidence of MACE after PCI，and has high safety.Its effective mechanism may be related to downregulating inflammatory factors and reducing oxidative stress response.
References:
［1］陈可冀,张敏州,霍勇.急性心肌梗死中西医结合诊疗专家共识［J］.中西医结合心脑血管病杂志,2014(6):389-395.
［2］Zhang WB，Liu LN，Liu Y，et al.Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention：A systematic review and meta-analysis.［J］.Medicine，2021，100(20)：e26070.
［3］顾俊,胡伟,肖红兵,等.主动脉内球囊反搏术在急性心肌梗死合并心源性休克患者冠状动脉介入术中的疗效评估［J］.中国介入心脏病学杂志,2009(1):9-11.
［4］Jayawardana S，Salasvega S，Cornehl F，et al.The relationship between off-hours admissions for primary percutaneous coronary intervention，door-to-balloon time and mortality for patients with ST-elevation myocardial infarction in England：a registry-based prospective national cohort study［J］.BMJ Quality And Safety，2020，29(7)：541-549.
［5］陈奇，刘洋，姬劲锐，等.西洛他唑联合氯吡格雷及阿司匹林对AMI病人PCI术后出血事件、凝血功能的影响［J］.中西医结合心脑血管病杂志，2022，20(7)：1279-1283.
［6］王旺，史波，叶小彬，等.黄芪桂枝五物汤加味对NSTE-ACS患者PCI术后NLR、hs-CRP、LP(α)的影响研究［J］.中国中医急症，2022，31(6)：1080-1082.
［7］勾圣乐，李莉，杨松琪，等.五参汤加减对急性心肌梗死患者经皮冠状动脉介入术术后心功能恢复的影响［J］.环球中医药，2021，14(11)：2083-2086.
［8］中华医学会心血管病学分会，中华心血管病杂志编辑委员会，《中国循环杂志》编辑委员会.急性心肌梗死诊断和治疗指南［J］.中华心血管病杂志，2001，29(12)：710-725.
［9］杨伟明.“胸痹”的探讨对冠心病心绞痛诊治的启发［C］//第四届中医药继续教育高峰论坛暨中华中医药学会继续教育分会换届选举会议论文集,2011.
［10］赵明芬,安冬青.胸痹心痛病因病机三期论［J］.中西医结合心脑血管病杂志,2008,6(7):833-834.
［11］胡冬裴.胸痹证治文献研究［J］.山东中医药大学学报,2005,29(1):37-40.
［12］杨志军，顾宁.中医药治疗急性心肌梗死后心力衰竭研究进展［J］.河北中医，2022，44(6)：1030-1034，1040.
［13］官晓欢，潘明垚，陆敬平，等.冠心病PCI术后心脏康复中医药应用的Meta分析［J］.云南中医中药杂志，2022，43(7)：38-46.
［14］陈旸，王靖.血府逐瘀汤加减配合针刺疗法对冠心病患者PCI术后临床效果及心理状态分析［J］.当代临床医刊，2022，35(3)：81-82.
［15］李娟霞，白灵彦，李晓旭，等.补阳还五汤加味对急性心肌梗死PCI术后患者血清EMPs、MMP-9及心功能和生活质量的影响［J］.现代中西医结合杂志，2021，30(11)：1221-1224，1240.
［16］莫春香，郭剑.瓜蒌薤白半夏汤结合硫酸氢氯吡格雷对改善痰浊闭阻型胸痹患者PCI术后预后的疗效观察［J］.贵州医药，2022，46(8)：1294-1295.
［17］李敏，丁念.五参汤加减联合常规治疗对急性心肌梗死PCI介入术后患者的临床疗效［J］.中成药，2021，43(7)：1968-1970.
［18］王晓琴，苏柯萌.北沙参化学成分与药理活性研究进展［J］.中国现代中药，2020，22(3)：466-474.
［19］付雪琴，兰瑞，邹旭欢，等.基于网络药理学研究丹参-川芎抗脑缺血再灌注损伤作用机制及试验验证［J］.中国畜牧兽医，2022，49(9)：3643-3654.
［20］李翎熙，陈迪路，周小江.玄参化学成分、药理活性研究进展及其质量标志物分析预测［J］.中成药，2020，42(9)：2417-2426.
［21］陈美慧，韩宇博，隋艳波，等.“黄芪-太子参”对慢性心力衰竭作用机制的网络药理学分析［J］.海南医学院学报，2022，28(9)：694-701.
［22］滕力庆，周涛，王晓，等.基于网络药理学和分子对接研究太子参抗心肌缺血的作用机制［J］.山东科学，2021，34(2)：24-33.
［23］付雪琴，兰瑞，邹旭欢，等.基于网络药理学研究丹参-川芎抗脑缺血再灌注损伤作用机制及试验验证［J］.中国畜牧兽医，2022，49(9)：3643-3654.
［24］白敏，刘烁，张娟利，等.基于网络药理学和分子对接探究川芎-丹参药对治疗心脑血管疾病的作用机制［J］.中国药师，2022，25(1)：18-26，48.
［25］陈祥洲，胡正，陈静.IL-6水平对STEMI患者接受直接PCI术后30天新发心衰的预测价值［J］.微循环学杂志，2022，32(4)：31-36.
［26］陈倍佳，朱席政.活血化瘀养心通络方治疗PCI术后心绞痛的疗效及对血清炎性因子水平的影响［J］.中西医结合心脑血管病杂志，2022，20(11)：2057-2061.
［27］谈昀，马兰香，张树苗，等.急性心肌梗死PCI术后支架内再狭窄患者的CRP、Hcy、CysC、NT-proBNP、LDL-C变化及临床意义［J］.海南医学，2022，33(14)：1799-1802.
［28］毛红岩.溶栓后行PCI治疗对AMI患者血清CRP及CTn-I与CK-MB水平的影响［J］.国际医药卫生导报，2019，25(17)：2966-2969.
［29］裴月皓，唐学弘，程国杰.冠心病患者介入治疗前后血清中TNF-α、IL-1β和caspase-1水平变化及意义［J］.中国循证心血管医学杂志，2021，13(7)：815-818.
［30］邹青，卢少平，张明明，等.FIB和TNF-α联合检测对冠心病患者PCI术后心肌缺血再灌注损伤的预测价值［J］.临床误诊误治，2021，34(6)：71-75.
Memo
基金项目：陕西省重点研发计划项目（S2017-ZDYF-YBXM-SF-0221）